NCT06360445View on ClinicalTrials.gov

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

August 21, 2022

Study Completion Date

August 21, 2022

Conditions
Healthy Participants
Interventions
DRUG

Olaparib Tablet test formulation 100mg

A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.

DRUG

Olaparib Tablet reference formulation 100mg

Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

DRUG

Olaparib Tablet test formulation 150mg

Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

DRUG

Olaparib Tablet reference formulation 150mg

Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

Trial Locations (1)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY